New Trial Data Bodes Well for Experimental Cerebral Adrenoleukodystrophy Gene Therapy
According to a story from pmlive.com, the gene therapy company Bluebird Bio's latest recently released results from the company's phase 2/3 clinical trial demonstrates further encouraging data for its Lenti-D…